The aim of our study was to clarify the HRR gene profile in Chinese SCLC patients and discuss the potential of HRR gene mutation status as a biomarker for response to PARP inhibitors, ICI therapy, or a combination of these two types of treatments. The gene discussed is PARP1; the disease is small cell lung carcinoma.